Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma

References

• Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447–8452.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121–3127.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540–1545.
   PubMed Web of Science ®Google Scholar
• Greene MH, Young RC, Merrill JM, et al. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma. Cancer Res 1983;43:1891–1898.
   PubMed Web of Science ®Google Scholar
• Curtis RE,Boice JD Jr, Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992;326:1745–1751.
   PubMed Web of Science ®Google Scholar
• Mudie NY, Swerdlow AJ, Higgins CD, et al. Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study. J Clin Oncol 2006;24:1568–1574.
   PubMed Web of Science ®Google Scholar
• Hemminki K, Lenner P, Sundquist J, et al. Risk of subsequent solid tumors after non-Hodgkin's lymphoma: effect of diagnostic age and time since diagnosis. J Clin Oncol 2008;26:1850–1857.
   PubMed Web of Science ®Google Scholar
• Morton LM, Curtis RE, Linet MS, et al. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol 2010;28:4935–4944.
   PubMed Web of Science ®Google Scholar
• Brennan P, Scelo G, Hemminki K, et al. Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma. Br J Cancer 2005;93:159–166.
   PubMed Web of Science ®Google Scholar
• Tward JD, Wendland MM, Shrieve DC, et al. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 2006;107:108–115.
   PubMed Web of Science ®Google Scholar
• Travis LB, Curtis RE, Glimelius B, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995;87:524–530.
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Ersboll J, Sorensen HM, et al. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann Intern Med 1985;103: 195–200.
   Google Scholar
• Travis LB, Curtis RE, Stovall M, et al. Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst 1994;86: 1450–1457.
   PubMed Web of Science ®Google Scholar
• Andre M, Mounier N, Leleu X, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood 2004;103:1222–1228.
   PubMed Web of Science ®Google Scholar
• Robison LL, Mertens A. Second tumors after treatment of childhood malignancies. Hematol Oncol Clin North Am 1993;7:401–415.
   PubMed Web of Science ®Google Scholar
• Sacchi S, Marcheselli L, Bari A, et al. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica 2008;93:398–404.
   PubMed Web of Science ®Google Scholar
• Brown JR, Yeckes H, Friedberg JW, et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2005;23:2208–2214.
   PubMed Web of Science ®Google Scholar
• Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 2003;101:2015–2023.
   PubMed Web of Science ®Google Scholar
• Tucker MA, Meadows AT, Boice JD Jr, et al. Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst 1987; 78:459–464.
   PubMed Web of Science ®Google Scholar
• Breslow NE, Day NE. Statistical methods in cancer research. Vol. I. The analysis of case-control studies. IARC Scientific Publications No. 32. 1980. Available from: http://www.iarc.fr/en/publications/pdfs-online/stat/sp32/index.php
   Google Scholar
• Turk JL, Parker D. Effect of cyclophosphamide on immunological control mechanisms. Immunol Rev 1982;65:99–113.
   PubMed Web of Science ®Google Scholar
• Przygodzki RM, Bennett WP, Guinee DG Jr, et al. p53 mutation spectrum in relation to GSTM1, CYP1A1 and CYP2E1 in surgically treated patients with non-small cell lung cancer. Pharmacogenetics 1998;8:503–511.
   PubMedGoogle Scholar
• Leonard DG, Travis LB, Addya K, et al. p53 mutations in leukemia and myelodysplastic syndrome after ovarian cancer. Clin Cancer Res 2002;8:973–985.
   PubMed Web of Science ®Google Scholar
• Lillington DM, Micallef IN, Carpenter E, et al. Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma. J Clin Oncol 2001;19:2472–2481.
   PubMed Web of Science ®Google Scholar
• Winick NJ, McKenna RW, Shuster JJ, et al. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 1993;11:209–217.
   PubMed Web of Science ®Google Scholar
• Travis LB, Holowaty EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999; 340:351–357.
   PubMed Web of Science ®Google Scholar
• Sacchi S, Marcheselli L, Bari A, et al. Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study. Haematologica 2008;93:1335–1342.
   PubMed Web of Science ®Google Scholar
• Pirani M, Marcheselli R, Marcheselli L, et al. Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis. Ann Oncol 2011;22:1845–1858.
   PubMed Web of Science ®Google Scholar
• Bhatia S, Meadows AT, Robison LL. Second cancers after pediatric Hodgkin's disease. J Clin Oncol 1998;16:2570–2572.
   PubMed Web of Science ®Google Scholar
• Koh ES, Tran TH, Heydarian M, et al. A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol 2007; 2:13.
   PubMed Web of Science ®Google Scholar
• De Bruin ML, Sparidans J, van't Veer MB, et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 2009;27:4239–4246.
   PubMed Web of Science ®Google Scholar
• Franklin J, Pluetschow A, Paus M, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol 2006;17:1749–1760.
   PubMed Web of Science ®Google Scholar
• Henry-Amar M. Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease. Ann Oncol 1992;3:117–128.
   PubMed Web of Science ®Google Scholar
• Biti G, Cellai E, Magrini SM, et al. Second solid tumors and leukemia after treatment for Hodgkin's disease: an analysis of 1121 patients from a single institution. Int J Radiat Oncol Biol Phys 1994; 29:25–31.
   PubMed Web of Science ®Google Scholar
• Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003;290:465–475.
   PubMed Web of Science ®Google Scholar
• Inskip PD, Robison LL, Stovall M, et al. Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol 2009;27:3901–3907.
   PubMed Web of Science ®Google Scholar
• Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002;94:182–192.
   PubMed Web of Science ®Google Scholar
• Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009;27: 5887–5892.
   PubMed Web of Science ®Google Scholar
• Nichols KE, Levitz S, Shannon KE, et al. Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease. J Clin Oncol 1999;17:1259.
   PubMed Web of Science ®Google Scholar
• Bernstein JL, Haile RW, Stovall M, et al. Radiation exposure, the ATM gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. J Natl Cancer Inst 2010;102:475–483.
   PubMed Web of Science ®Google Scholar
• Narod SA, Lubinski J, Ghadirian P, et al. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol 2006;7:402–406.
   PubMed Web of Science ®Google Scholar
• de Berrington GA, Berg CD, Visvanathan K, et al. Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers. J Natl Cancer Inst 2009;101:205–209.
   PubMed Web of Science ®Google Scholar
• Mellemkjoer L, Olsen JH, Linet MS, et al. Cancer risk after splenectomy. Cancer 1995;75:577–583.
   PubMed Web of Science ®Google Scholar
• Linet MS, Nyren O, Gridley G, et al. Risk of cancer following splenectomy. Int J Cancer 1996;66:611–616.
   PubMed Web of Science ®Google Scholar
• Chung CT, Bogart JA, Adams JF, et al. Increased risk of breast cancer in splenectomized patients undergoing radiation therapy for Hodgkin's disease. Int J Radiat Oncol Biol Phys 1997;37:405–409.
   PubMed Web of Science ®Google Scholar
• Kaldor JM, Day NE, Pettersson F, et al. Leukemia following chemotherapy for ovarian cancer. N Engl J Med 1990;322:1–6.
   PubMed Web of Science ®Google Scholar
• Rowley DA. The formation of circulating antibody in the splenectomized human being following intravenous injection of heterologous erythrocytes. J Immunol 1950;65:515–521.
   PubMed Web of Science ®Google Scholar
• Constantopoulos A, Najjar VA, Wish JB, et al. Defective phagocytosis due to tuftsin deficiency in splenectomized subjects. Am J Dis Child 1973;125:663–665.
   PubMedGoogle Scholar
• Seshadri T, Pintilie M, Kuruvilla J, et al. Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Leuk Lymphoma 2009;50: 380–386.
   PubMed Web of Science ®Google Scholar